GlassScriptPhysician profile
Rachana Oak
NPI 1265842868
$5,422.23
in general payments reported to CMS, 2019-2025
28 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.04 · 2020: $66.67 · 2021: $286 · 2022: $650 · 2023: $1,354 · 2024: $1,142 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,388 · Education: $11.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,388.21 |
| Education | $11.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,871.82 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $814.89 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $368.56 | 2022-2025 | Ibsrela |
| Pfizer INC. | $212.50 | 2023-2025 | |
| Genzyme Corporation | $197.22 | 2023-2025 | |
| Boston Scientific Corporation | $194.98 | 2019-2025 | Axios |
| Takeda Pharmaceuticals U.S.A., INC. | $192.61 | 2021-2025 | Entyvio, Eohilia |
| Ironwood Pharmaceuticals, INC | $182.02 | 2023-2025 | Linzess |
| Celgene Corporation | $149.75 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $135.83 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $120.57 | 2022-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $109.22 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $107.98 | 2022-2024 | Dificid |
| Daiichi Sankyo INC. | $105.07 | 2022-2024 | Injectafer |
| Janssen Biotech, INC. | $90.73 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $87.47 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $71.69 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Gilead Sciences, INC. | $67.01 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $63.26 | 2022-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $49.74 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.92 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $43.22 | 2023 | Sutab, Suflave |
| Olympus America INC. | $41.18 | 2021 | |
| Exact Sciences Corporation | $27.99 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $21.30 | 2024 | Omvoh |
| Evoke Pharma, INC. | $19.97 | 2024 | |
| Aimmune Therapeutics, INC. | $16.43 | 2024 | |
| Capsovision, INC. | $15.30 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachana Oak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.